{"id":8818,"date":"2021-03-19T10:18:55","date_gmt":"2021-03-19T10:18:55","guid":{"rendered":"https:\/\/zeepedia.com\/?p=8818"},"modified":"2021-04-12T14:39:56","modified_gmt":"2021-04-12T14:39:56","slug":"flebogamma-dif","status":"publish","type":"post","link":"https:\/\/zeepedia.com\/medical\/medicines\/flebogamma-dif\/","title":{"rendered":"Flebogamma DIF -Human Normal Immunoglobulin uses, dose and side effects"},"content":{"rendered":"\n<p>\n\n50 mg \/ ml&nbsp;solution for infusion&nbsp;.<br>Human normal immunoglobulin (IVIg)<\/p>\n\n\n\n<h2 class=\"wp-block-heading\">1. What Flebogamma DIF is and what it is used for<\/h2>\n\n\n\n<p><strong>What Flebogamma DIF is<\/strong><\/p>\n\n\n\n<p>Phlebogamma DIF contains human normal immunoglobulin, a highly purified&nbsp;protein&nbsp;derived from&nbsp;human&nbsp;plasma&nbsp;(part of the blood from blood donors).&nbsp;It belongs to a group of medicines called immunoglobulin for&nbsp;intravenous&nbsp;use.&nbsp;These are used to treat conditions where the body&#8217;s defenses against infection do not work properly.<\/p>\n\n\n\n<h2 class=\"wp-block-heading\">What Flebogamma DIF is used for<\/h2>\n\n\n\n<p>Treatment of adults, children, and adolescents (2-18 years) who do not have enough&nbsp;antibodies&nbsp;(Flebogamma DIF is used as&nbsp;substitution&nbsp;therapy&nbsp;).&nbsp;There are TV groups:<br><\/p>\n\n\n\n<ul class=\"wp-block-list\"><li>Patients with primary immunodeficiency syndrome (PID) with congenital deficiency of&nbsp;antibodies&nbsp;(group 1).<\/li><li>Patients with secondary immunodeficiency (SID) with severe or recurrent&nbsp;infection, ineffective&nbsp;antimicrobial&nbsp;treatment, and either&nbsp;<strong>inability to respond to a specific&nbsp;antigen, so-called PSAF<\/strong>&nbsp;(&nbsp;<em>proven specific&nbsp;antibody&nbsp;failure<\/em>&nbsp;) * or IgG levels in&nbsp;serum&nbsp;&lt;4 g \/ l (group 2).<\/li><\/ul>\n\n\n\n<p>* PDF = inability to obtain at least one doubled IgG antibody titer against pneumococcal polysaccharide and polypeptide antigen vaccines.<br><\/p>\n\n\n\n<p>Treatment of adults, children, and adolescents (2\u201318 years) with certain autoimmune diseases (immune modulation).&nbsp;There are five groups:<\/p>\n\n\n\n<ul class=\"wp-block-list\"><li>Primary immune&nbsp;thrombocytopenia&nbsp;(ITP) is a condition in which the number of&nbsp;platelets&nbsp;in the blood has decreased sharply.&nbsp;Platelets play an important role in blood clotting and patients who do not have enough&nbsp;platelets are&nbsp;at high risk for unwanted bleeding and bruising.&nbsp;The drug is also used in patients at high risk of bleeding or who will be operated on shortly.<\/li><li>Guillain-Barr\u00e9 syndrome in&nbsp;which the immune system damages the nerves and prevents them from functioning properly.<\/li><li>Kawasaki disease (in this case together with treatment with&nbsp;aspirin&nbsp;), a disease in children where the blood vessels (&nbsp;arterial&nbsp;s) in the body are enlarged.<\/li><li>Chronic&nbsp;inflammatory&nbsp;demyelinating polyradiculoneuropathy (CIDP), a rare and&nbsp;progressive&nbsp;disease that causes weakness in the arms and legs, numbness, pain, and fatigue.<\/li><li>Multifocal&nbsp;motor&nbsp;neuropathy&nbsp;(MMN), a rare disease that causes slowly progressing asymmetric weakness in the arms and legs without loss of sensation.<\/li><\/ul>\n\n\n\n<h2 class=\"wp-block-heading\">2. What you need to know before using Flebogamma DIF<\/h2>\n\n\n\n<h2 class=\"wp-block-heading\">Do not use Flebogamma DIF<\/h2>\n\n\n\n<ul class=\"wp-block-list\"><li>if you are allergic to human normal immunoglobulin or any of the other ingredients of this medicine (listed in section 6)<\/li><li>if you do not have enough immunoglobulins of the type&nbsp;IgA&nbsp;in your blood or have developed&nbsp;IgA&nbsp;antibody&nbsp;is<\/li><li>If you suffer from&nbsp;fructose intolerance, a very rare inherited disease, the&nbsp;enzyme&nbsp;that breaks down fructose is&nbsp;not produced.&nbsp;Infants and young children (0-2 years) should not use this medicine as they may not yet be diagnosed with hereditary&nbsp;fructose intolerance&nbsp;(&nbsp;hereditary&nbsp;fructose intolerance, HFI), which can be fatal.&nbsp;(see special warnings about excipients at the end of this section).<\/li><\/ul>\n\n\n\n<h2 class=\"wp-block-heading\">Warnings and cautions<\/h2>\n\n\n\n<p>Talk to your doctor, pharmacist, or nurse before using Flebogamma DIF.<br><\/p>\n\n\n\n<p>Some&nbsp;side effects&nbsp;may occur more often:<\/p>\n\n\n\n<ul class=\"wp-block-list\"><li>at high infusion rate.<\/li><li>if this is the first time you are receiving Flebogamma DIF, or when switching from a product with human normal immunoglobulin (IVIg), or if it is a long time since your last&nbsp;infusion&nbsp;(eg several weeks), you will be closely monitored for up to one hour after&nbsp;infusion&nbsp;to detect&nbsp;signs of possible&nbsp;side effects.<\/li><\/ul>\n\n\n\n<p>Allergic reactions are rare.&nbsp;This can happen especially if you do not have enough&nbsp;IgA-&nbsp;type immunoglobulin&nbsp;in your blood or have developed&nbsp;antibodies&nbsp;to&nbsp;IgA.<br><\/p>\n\n\n\n<p><em>Patients with previous risk factors<\/em><\/p>\n\n\n\n<p>Tell your doctor if you have any other condition and\/or disease, as control is required in patients with pre-existing risk factors for thrombotic events (blood clots form in your blood).&nbsp;Be especially careful to tell your doctor if you have:<\/p>\n\n\n\n<ul class=\"wp-block-list\"><li>diabetes<\/li><li>high&nbsp;blood pressure<\/li><li>previously affected by vascular disease or&nbsp;thrombosis<\/li><li>overweight<\/li><li>decreased blood volume<\/li><li>a disease that increases blood viscosity (blood sluggishness unit)<\/li><li>age over 65 years<\/li><\/ul>\n\n\n\n<p><em>Patients with kidney problems<\/em><\/p>\n\n\n\n<p>If you have kidney disease and this is the first time you are getting Flebogamma DIF, you may have kidney problems.<br><\/p>\n\n\n\n<p>Your doctor will consider your risk factors and take measures such as reducing the&nbsp;infusion&nbsp;or stopping treatment.<br><\/p>\n\n\n\n<p><em>Effects on blood tests<\/em><\/p>\n\n\n\n<p>After receiving Flebogamma DIF, the results of certain blood tests (serological tests) may be affected for some time.&nbsp;If you are taking a blood sample after receiving Flebogamma DIF, inform the person taking the sample or your doctor that you are taking this medicine.<br><\/p>\n\n\n\n<p><em>Special safety warning<\/em><\/p>\n\n\n\n<p>When drugs are made from human blood or&nbsp;plasma,&nbsp;several measures are taken to prevent the&nbsp;transmission of&nbsp;infection&nbsp;to patients.&nbsp;This includes:<\/p>\n\n\n\n<ul class=\"wp-block-list\"><li>careful selection of blood and plasma donors to ensure that those who can carry&nbsp;your&nbsp;infection&nbsp;have been excluded<\/li><li>testing of all donations and collections of&nbsp;plasma&nbsp;for signs of open viruses\/infections<\/li><li>introduction of blood or&nbsp;plasma&nbsp;processing measures&nbsp;that can inactivate or remove&nbsp;viruses.<\/li><\/ul>\n\n\n\n<p>Despite these measures, the risk of transmission of infectious agents cannot be completely ruled out when medicinal products derived from human blood or&nbsp;plasma&nbsp;are administered.&nbsp;This also applies to new, hitherto unknown&nbsp;viruses&nbsp;or other types of&nbsp;infection.<br><\/p>\n\n\n\n<p>The measures taken are considered to be effective for enveloped&nbsp;viruses&nbsp;such as human immunodeficiency virus (&nbsp;HIV&nbsp;),&nbsp;hepatitis&nbsp;B&nbsp;virus,&nbsp;or&nbsp;hepatitis&nbsp;C&nbsp;virus,s,&nbsp;and the non-enveloped&nbsp;hepatitis&nbsp;A&nbsp;virus&nbsp;or parvovirus B19.<br><\/p>\n\n\n\n<p>Immunoglobulins have not been associated with&nbsp;hepatitis&nbsp;A or parvovirus B19&nbsp;infection&nbsp;possibly because&nbsp;antibodies&nbsp;to these&nbsp;infections, which are present in the product, are protective.<br><\/p>\n\n\n\n<p>It is strongly recommended that the product name and batch number (indicated on the label and carton after Lot) be registered each time Flebogamma DIF is administered to maintain a register of used batches.<br><\/p>\n\n\n\n<p><strong>Children and young people<\/strong><\/p>\n\n\n\n<p>Vital signs (body temperature,&nbsp;blood pressure, heart rate, and respiratory rate) should be followed during&nbsp;infusion&nbsp;one of Flebogamma DIF.<\/p>\n\n\n\n<h2 class=\"wp-block-heading\">Other medicines and Flebogamma DIF<\/h2>\n\n\n\n<ul class=\"wp-block-list\"><li>Tell your doctor or pharmacist if you are taking or have recently taken any other medicines.<\/li><li>Vaccine effects: Flebogamma DIF may reduce the effect of certain types of vaccines (live attenuated viral vaccines).&nbsp;In cases such as rubella, mumps, and chickenpox, a period of up to 3 months should run from the time you receive the medicine until you receive the vaccine.&nbsp;In the case of measles, this period is up to one year.<\/li><li>You should avoid using concomitant medicines that increase the excretion of water from the body (loop diuretics) during treatment with Flebogamma DIF.<\/li><\/ul>\n\n\n\n<h2 class=\"wp-block-heading\">Pregnancy and breastfeeding<\/h2>\n\n\n\n<p>If you are pregnant or breast-feeding, think you may be pregnant, or are planning to have a baby, ask your doctor or pharmacist for advice before taking this medicine.<\/p>\n\n\n\n<h2 class=\"wp-block-heading\">Driving and using machines<\/h2>\n\n\n\n<p>Patients may experience reactions (such as dizziness and nausea) during treatment that may affect their ability to drive and use machines.<\/p>\n\n\n\n<h2 class=\"wp-block-heading\">Flebogamma DIF contains sorbitol<\/h2>\n\n\n\n<p>This medicine contains 50 mg sorbitol per ml.&nbsp;If you have been told by your doctor that you have an intolerance to some sugars, contact your doctor before taking this medicine.<\/p>\n\n\n\n<p><strong>In people older than 2&nbsp;years who do not tolerate fructose, a spontaneous reaction to fructose-containing food develops which can cause the following symptoms: vomiting, disorders of the gastrointestinal tract,&nbsp;apathy, poor height growth, and weight loss.&nbsp;Therefore, patients should be carefully examined for symptoms of hereditary&nbsp;fructose intolerance&nbsp;before receiving Flebogamma DIF.<\/strong><br><\/p>\n\n\n\n<p><strong>Flebogamma DIF contains&nbsp;sodium<\/strong><\/p>\n\n\n\n<p>This medicine contains less than 1 mmol (23 mg)&nbsp;sodium&nbsp;per&nbsp;vial&nbsp;of 10 ml, 50 ml, 100 ml, and 200 ml, ie essentially &#8216;sodium-free&#8217;.&nbsp;This product contains less than 29.41 mg&nbsp;sodium&nbsp;(the main ingredient in saline\/table salt) per&nbsp;vial&nbsp;with 400 ml.&nbsp;This corresponds to 1.5% of the highest recommended daily intake of&nbsp;sodium&nbsp;for adults.&nbsp;Depending on the&nbsp;dose&nbsp;prescribed by your doctor, you may receive more than 1&nbsp;vial.<br><\/p>\n\n\n\n<h2 class=\"wp-block-heading\">3. How to use Flebogamma DIF<\/h2>\n\n\n\n<p>Flebogamma DIF is given as an&nbsp;injection&nbsp;into a vein (&nbsp;intravenous&nbsp;administration&nbsp;).&nbsp;It can be given by yourself if you have received full training from hospital staff.&nbsp;You need to prepare the&nbsp;infusion&nbsp;exactly as you were shown to prevent bacteria from entering.&nbsp;You must never give it to yourself when you are alone;&nbsp;a responsible adult must always be present.<br><\/p>\n\n\n\n<p>The&nbsp;dose&nbsp;you receive varies depending on your illness and body weight and is calculated by your doctor (see section Instructions for healthcare professionals, given at the end of this leaflet).<br><\/p>\n\n\n\n<p>At the beginning of&nbsp;infusion&nbsp;one, you will receive Flebogamma DIF at a slow rate (0.01-0.02 ml\/kg\/min).&nbsp;Depending on how you feel, your doctor may then slowly increase the infusion rate (up to 0.1 ml\/kg\/min).<br><\/p>\n\n\n\n<p><strong>Use for children&nbsp;<\/strong><strong>over 2 years of age<\/strong><\/p>\n\n\n\n<p>Dose&nbsp;one in children is not considered different than in adults because&nbsp;dosage&nbsp;one is given according to the child&#8217;s disease and body weight.<\/p>\n\n\n\n<h2 class=\"wp-block-heading\">If you take more Flebogamma DIF then you should<\/h2>\n\n\n\n<p>If you ingest more Flebogamma DIF than you should, your body may accumulate too much fluid.&nbsp;This can happen especially if you are a risk patient, e.g.&nbsp;an elderly patient or a patient who has heart or kidney problems.&nbsp;Tell your doctor immediately.<\/p>\n\n\n\n<h2 class=\"wp-block-heading\">If you forget to take Flebogamma DIF<\/h2>\n\n\n\n<p>Tell your doctor or pharmacist immediately and follow his \/ her instructions.<\/p>\n\n\n\n<p>You must not be given a double&nbsp;dose&nbsp;to make up for a forgotten&nbsp;dose.<br><\/p>\n\n\n\n<p>If you have any further questions on the use of this product, ask your doctor, pharmacist, or nurse.<\/p>\n\n\n\n<h2 class=\"wp-block-heading\">4. Possible side effects<\/h2>\n\n\n\n<p>Like all medicines, this medicine can cause&nbsp;side effects,&nbsp;although not everybody gets them.<br><\/p>\n\n\n\n<p>In rare and isolated cases, the following&nbsp;side effects have&nbsp;been reported for immunoglobulin drugs.&nbsp;<strong>Seek medical attention without delay if any of the following&nbsp;side effects&nbsp;occur during or after the infusion:<\/strong><\/p>\n\n\n\n<ul class=\"wp-block-list\"><li>A sudden drop in blood pressure and, in some cases, anaphylactic&nbsp;shock&nbsp;(signs of this may include rash, low&nbsp;blood pressure, palpitations, wheezing, coughing, sneezing, and difficulty breathing) even if you have not shown any hypersensitivity when previously given the medicine.<\/li><li>Cases of transient&nbsp;meningitis&nbsp;(signs of this may be headache, photosensitivity or light intolerance, neck stiffness).<\/li><li>Cases of a transient decrease in&nbsp;red blood cell count&nbsp;(&nbsp;reversible&nbsp;hemolytic anemia\/hemolysis).<\/li><li>Cases of transient skin reactions (&nbsp;side effects&nbsp;on the skin).<\/li><li>Increased&nbsp;serum&nbsp;creatinine content&nbsp;(a test that measures your kidney function) and\/or&nbsp;acute&nbsp;renal impairment (signs of this are low back pain, fatigue, decreased amount of urine).<\/li><li>Blood clots such as heart attack (pressure over the chest with the feeling that the heart is beating too fast), stroke (muscle weakness in the face, arms, or legs, difficulty speaking or understanding other people&#8217;s speech), blood clots in the lungs (shortness of breath, chest pain, and fatigue), deep&nbsp;vein thrombosis&nbsp;(pain and swelling in one&nbsp;extremity&nbsp;).<\/li><li>Cases of transfusion-related&nbsp;acute&nbsp;lung injury (TRALI) causing&nbsp;hypoxia&nbsp;(lack of oxygen),&nbsp;dyspnoea&nbsp;(difficulty breathing),&nbsp;tachypnea&nbsp;(rapid breathing), cyanosis (lack of oxygen in the blood), fever, and&nbsp;hypotension&nbsp;(low&nbsp;blood pressure&nbsp;).<\/li><\/ul>\n\n\n\n<p><em>Other side effects:<\/em><\/p>\n\n\n\n<p><em><strong>V&nbsp;antigen (may affect up to 1 in 10 people):<\/strong><\/em><\/p>\n\n\n\n<ul class=\"wp-block-list\"><li>headache<\/li><li>fever (elevated body temperature)<\/li><li>tachycardia&nbsp;(rapid heartbeat)<\/li><li>low&nbsp;blood pressure<\/li><\/ul>\n\n\n\n<p><em><strong>Uncommon (may affect up to 1 in 100 people):<\/strong><\/em><\/p>\n\n\n\n<ul class=\"wp-block-list\"><li>bronchitis&nbsp;(&nbsp;tracheal catarrh&nbsp;)<\/li><li>nasopharyngitis&nbsp;\/ (cold symptoms)<\/li><li>dizziness (motion sickness)<\/li><li>high&nbsp;blood pressure<\/li><li>high&nbsp;blood pressure<\/li><li>hissing breathing<\/li><li>Mud-mixed cough<\/li><li>abdominal pain (also includes upper abdomen)<\/li><li>diarrhea<\/li><li>vomiting<\/li><li>nausea<\/li><li>urticaria&nbsp;(&nbsp;hives&nbsp;)<\/li><li>pruritus&nbsp;(&nbsp;itching&nbsp;)<\/li><li>rash<\/li><li>back pain<\/li><li>myalgia&nbsp;(muscle pain)<\/li><li>arthralgia&nbsp;(joint pain)<\/li><li>frostbite<\/li><li>pain<\/li><li>injection site reaction<\/li><li>positive Coombs test<\/li><li>lowered&nbsp;blood pressure<\/li><\/ul>\n\n\n\n<p><strong><em>Rare (may affect up to 1 in 1,000&nbsp;infusions&nbsp;):<\/em><\/strong><\/p>\n\n\n\n<ul class=\"wp-block-list\"><li>hypersensitivity<\/li><li>abnormally behaving<\/li><li>migraine<\/li><li>fluctuating&nbsp;blood pressure<\/li><li>herds (to blush)<\/li><li>cough<\/li><li>asthma<\/li><li>dyspnoea&nbsp;(difficulty breathing)<\/li><li>epistaxis&nbsp;(nosebleeds)<\/li><li>discomfort from the nose<\/li><li>pain in the throat<\/li><li>contact dermatitis<\/li><li>hyperhidrosis&nbsp;(heavy sweating)<\/li><li>rash<\/li><li>muscle twitching<\/li><li>neck pain<\/li><li>pain in arms and legs<\/li><li>urinary retention&nbsp;(difficulty urinating)<\/li><li>asthenia&nbsp;(weakness)<\/li><li>chest pain<\/li><li>infusion site reactions (&nbsp;redness, drug leakage,&nbsp;inflammation,&nbsp;and pain)<\/li><li>injection site reactions (such as&nbsp;edema, pain,&nbsp;itching,&nbsp;and swelling)<\/li><li>fluid accumulation in the arms and legs (peripheral&nbsp;edema&nbsp;)<\/li><li>elevated&nbsp;alanine aminotransferase&nbsp;(liver transaminase)<\/li><li>movement of e.g.&nbsp;needle or infusion line<\/li><\/ul>\n\n\n\n<p><strong>Additional&nbsp;side effects&nbsp;are in children and adolescents<\/strong><\/p>\n\n\n\n<p>The proportion of headache, fever, increased heart rate, and low&nbsp;blood pressure&nbsp;in children was found to be higher than in adults.<br><\/p>\n\n\n\n<p><strong>Reporting of&nbsp;side effects&nbsp;ar<\/strong><\/p>\n\n\n\n<p>If you get&nbsp;any side effects, talk to your doctor, pharmacist, or nurse.&nbsp;This also applies to side effects that are not mentioned in this information.&nbsp;By reporting&nbsp;side effects, you can help increase drug safety information.<br><\/p>\n\n\n\n<h2 class=\"wp-block-heading\">5. How to store Flebogamma DIF<\/h2>\n\n\n\n<p>Keep this medicine out of the sight and reach of children.<br><\/p>\n\n\n\n<p>Do not use this medicine after the expiry date which is stated on the carton after \u201cEXP\u201d.<br><\/p>\n\n\n\n<p>Do not store above 30 \u00b0 C.&nbsp;Do not freeze.<br><\/p>\n\n\n\n<p>The solution should be clear to slightly translucent.&nbsp;Do not use this medicine if you find that the solution is cloudy or contains&nbsp;precipitates.<br><\/p>\n\n\n\n<p>Medicines should not be disposed of via wastewater or household waste.&nbsp;Ask your pharmacist how to dispose of medicines no longer required.&nbsp;These measures will help to protect the environment.<\/p>\n\n\n\n<h2 class=\"wp-block-heading\">6. Contents of the packaging and other information<\/h2>\n\n\n\n<h2 class=\"wp-block-heading\">Content declaration<\/h2>\n\n\n\n<p>The active substance is human normal immunoglobulin (IVIg).&nbsp;One ml contains 50 mg of human normal immunoglobulin of which at least 97% is IgG.<br><\/p>\n\n\n\n<p>Each&nbsp;vial&nbsp;with 10 ml: 0.5 g of normal human<\/p>\n\n\n\n<p>Each&nbsp;vial&nbsp;with 50 ml: 2.5 g of normal human<\/p>\n\n\n\n<p>Each&nbsp;vial&nbsp;with 100 ml: 5 g of normal human<\/p>\n\n\n\n<p>Each&nbsp;vial&nbsp;with 200 ml: 10 g of normal human<\/p>\n\n\n\n<p>Each&nbsp;vial&nbsp;with 400 ml: 20 g of normal human<br><\/p>\n\n\n\n<p>Distribution of IgG subclasses is approximately 66.6% IgG&nbsp;<sub>1<\/sub>&nbsp;, 28.5% IgG&nbsp;<sub>2<\/sub>&nbsp;, 2.7% IgG&nbsp;<sub>3<\/sub>&nbsp;and 2.2% IgG&nbsp;<sub>4<\/sub>&nbsp;.&nbsp;The product contains trace amounts of&nbsp;IgA&nbsp;(less than 0.05 mg \/ ml).<br><\/p>\n\n\n\n<p>The other ingredients are sorbitol and water for injections (see section 2 for more information on the ingredients).<br><\/p>\n\n\n\n<p><strong>What the medicine looks like and the contents of the pack<\/strong><\/p>\n\n\n\n<p>Flebogamma DIF is an&nbsp;infusion&nbsp;solution.&nbsp;The solution is clear or slightly translucent and colorless or slightly yellow.<br><\/p>\n\n\n\n<p>Flebogamma DIF is supplied in vials of 0.5 g \/ 10 ml, 2.5 g \/ 50 ml, 5 g \/ 100 ml, 10 g \/ 200 ml and 20 g \/ 400 ml.<\/p>\n\n\n\n<p>Pack size: 1&nbsp;vial.<\/p>\n\n\n\n<p>Not all volumes may be marketed.<\/p>\n\n\n\n<h2 class=\"wp-block-heading\">Marketing Authorization Holder and Manufacturer<\/h2>\n\n\n\n<p>Instituto Grifols, SA<\/p>\n\n\n\n<p>Can Guasc, 2 &#8211; Parets del Vall\u00e8s<\/p>\n\n\n\n<p>08150 Barcelona &#8211; Spain<br><\/p>\n\n\n\n<p>Contact the representative of the marketing authorization holder to find out more about this medicine:<\/p>\n\n\n\n<figure class=\"wp-block-table\"><table><tbody><tr><td><strong>AT \/ BE \/ BG \/ CY \/ EE \/ EL \/ ES \/ HR \/ HU \/ IE \/ LV \/<\/strong><strong>LT \/ LU \/ MT \/ NL \/ RO \/ SI \/ SK<\/strong>Instituto Grifols, SATel: +34 93 571 01 00<\/td><td><strong>CZ<\/strong>Grifols SROTel: +4202 2223 1415<\/td><\/tr><tr><td><strong>THE<\/strong>Grifols Deutschland GmbHTel: +49 69 660 593 100<\/td><td><strong>DK \/ FI \/ IS \/ NO \/ SE<\/strong>Grifols Nordic ABTel: +46 8 441 89 50<\/td><\/tr><tr><td><strong>FR<\/strong>Laboratory Novex PharmaTel: +33 (0) 1 41 27 59 56<\/td><td><strong>IT<\/strong>Grifols Italia SpATel: +39 050 8755 113<\/td><\/tr><tr><td><strong>PL<\/strong>Grifols Polska Sp.&nbsp;z ooTel: +48 22 378 85 60<\/td><td><strong>PT<\/strong>Grifols Portugal, Lda.Tel: +351 219 255 200<\/td><\/tr><tr><td><strong>UK<\/strong>Grifols UK Ltd.Tel: +44 845 2413090<\/td><td><\/td><\/tr><\/tbody><\/table><\/figure>\n\n\n\n<p><\/p>\n","protected":false},"excerpt":{"rendered":"<p>50 mg \/ ml solution for infusion .<br \/>\nHuman normal immunoglobulin (IVIg)<\/p>\n","protected":false},"author":2,"featured_media":0,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"cybocfi_hide_featured_image":"","footnotes":""},"categories":[2206,2200],"tags":[2832,2834,2835,2833,2828,2830,2831,2829,2235,2212],"class_list":["post-8818","post","type-post","status-publish","format-standard","hentry","category-f","category-medicines","tag-flebogamma-dif","tag-flebogamma-dif-dose","tag-flebogamma-dif-side-effects","tag-flebogamma-dif-uses","tag-human-normal-immunoglobulin","tag-human-normal-immunoglobulin-dose","tag-human-normal-immunoglobulin-side-effects","tag-human-normal-immunoglobulin-uses","tag-infusion","tag-medicine"],"_links":{"self":[{"href":"https:\/\/zeepedia.com\/medical\/wp-json\/wp\/v2\/posts\/8818","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/zeepedia.com\/medical\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/zeepedia.com\/medical\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/zeepedia.com\/medical\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/zeepedia.com\/medical\/wp-json\/wp\/v2\/comments?post=8818"}],"version-history":[{"count":5,"href":"https:\/\/zeepedia.com\/medical\/wp-json\/wp\/v2\/posts\/8818\/revisions"}],"predecessor-version":[{"id":9966,"href":"https:\/\/zeepedia.com\/medical\/wp-json\/wp\/v2\/posts\/8818\/revisions\/9966"}],"wp:attachment":[{"href":"https:\/\/zeepedia.com\/medical\/wp-json\/wp\/v2\/media?parent=8818"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/zeepedia.com\/medical\/wp-json\/wp\/v2\/categories?post=8818"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/zeepedia.com\/medical\/wp-json\/wp\/v2\/tags?post=8818"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}